About
NGN Capital is a venture capital firm that specializes in managing investment funds for the healthcare and biotechnology sectors. The firm strategically deploys capital into companies developing drug products, medical devices, and other biomedical innovations, focusing on opportunities across North America and Europe. NGN Capital was founded on the insight that targeted investment in the rapidly evolving healthcare and life sciences industries could yield substantial returns while advancing critical medical solutions. The firm's long-term vision centers on fostering a robust ecosystem of innovation, empowering visionary entrepreneurs to transform their pioneering concepts into successful ventures, thereby driving progress within the global technology arena.
Portfolio
Investment activity
2 portfolio exits on record.
Portfolio by sector
Q&A
- What is NGN Capital's most recent exit?
- NGN Capital's most recent exit was Cardiovalve, which was acquired by Venus Medtech in March 2022 for $150M.
- What is NGN Capital's sector focus?
- NGN Capital primarily focuses on the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.
- Can you name some of NGN Capital's notable portfolio companies?
- NGN Capital's notable portfolio companies include Cardiovalve and Valtech Cardio, both of which have been acquired.
- What was NGN Capital's first recorded exit?
- NGN Capital's first recorded exit was Valtech Cardio, which was acquired by Edwards Lifesciences in January 2017 for $340M.
- What is the typical investment range for NGN Capital?
- NGN Capital's investment range is between $17.8M and $40M.
- How many exits has NGN Capital had in the last five years?
- NGN Capital has had one exit in the last five years, with Cardiovalve being acquired in March 2022.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2003 |
|---|